Powles, Thomas http://orcid.org/0000-0001-7760-4724
Yuen, Kobe C.
Gillessen, Silke
Kadel, Edward E. III http://orcid.org/0000-0003-3030-6628
Rathkopf, Dana
Matsubara, Nobuaki
Drake, Charles G. http://orcid.org/0000-0001-9610-3677
Fizazi, Karim
Piulats, Josep M.
Wysocki, Piotr J. http://orcid.org/0000-0003-4003-5278
Buchschacher, Gary L. Jr
Alekseev, Boris
Mellado, Begoña
Karaszewska, Bogusława
Doss, Jennifer F.
Rasuo, Grozdana
Datye, Asim
Mariathasan, Sanjeev
Williams, Patrick http://orcid.org/0000-0003-4168-9433
Sweeney, Christopher J. http://orcid.org/0000-0002-0398-6018
Funding for this research was provided by:
Roche
Genentech
Article History
Received: 23 April 2021
Accepted: 2 November 2021
First Online: 10 January 2022
Competing interests
: T.P. received honoraria from advisory/consultancy roles with AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD Serono), Astellas, Johnson & Johnson, Eisai and Roche; institutional research funding support from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono (EMD Serono), Astellas and Johnson & Johnson; and travel, accommodation and expenses support from Roche, Pfizer, MSD, AstraZeneca and Ipsen. S.G. received honoraria from Janssen; advisory/consultancy fees to the institution from Active Biotech, Astellas Pharma, Bayer, Bristol Myers Squibb, Clovis Oncology, CureVac, Ferring, Innocrin, Janssen, Menarini Silicon Biosystems and Novartis; advisory/consultancy fees from Advanced Accelerator Applications, Amgen, MaxiVax, Orion Pharma, Roche and Sanofi; and travel, accommodations and expenses from Nektar and ProteoMediX. S.G. also holds a patent involving a method for biomarker (no. WO 3752009138392 A1). K.C.Y. is an employee of Genentech and has stock ownership of Roche. E.E.K. is an employee of Genentech and has stock ownership of Roche, Clinuvel, Epizyme, Mannkind and Merck. D.R. received advisory/consultancy fees from AstraZeneca, Bayer, Genentech and Janssen; and institutional research funding support from AstraZeneca, Celgene, Ferring, Genentech/Roche, Janssen, Medivation, Millennium, Novartis, Taiho Pharmaceutical, Takeda and TRACON. N.M. received advisory/consultancy fees from Janssen, MSD, Chugai and Sanofi; and institutional research funding support from Janssen, MSD, Chugai, Astellas, Eli Lilly, Taiho and Pfizer. C.D. received advisory/consultancy fees from AstraZeneca/MedImmune, Bristol Myers Squibb, Compugen, Janssen Oncology, Merck, Pfizer, Pierre Fabre, Potenza Therapeutics, Roche/Genentech and Tizona Therapeutics; received institutional research funding support from Bristol Myers Squibb; owns stock and other ownership interests in Compugen, Harpoon Therapeutics, Kleo Pharmaceuticals and Tizona Therapeutics; and received travel, accommodations and expenses support from AACR, ASCO, Merck Sharp & Dohme, Pfizer and Roche/Genentech. C.D. also licenses patents through the institution to Bristol Myers Squibb and Potenza Therapeutics. K.F. received honoraria from Astellas Pharma, Janssen and Sanofi; received advisory/consultancy fees from Amgen, Astellas Pharma, AstraZeneca, Bayer, CureVac, ESSA Pharma, Janssen Oncology, Orion Pharma, Roche/Genentech and Sanofi; and travel, accommodations and expenses support from Amgen and Janssen. J.M.P. received advisory/consultancy fees from Astellas Pharma, Bristol Myers Squibb, Clovis Oncology, Janssen Oncology, Merck Sharp & Dohme, Roche/Genentech and VCN Biosciences; research funding support from AstraZeneca/MedImmune, Bristol Myers Squibb, Incyte, Janssen Oncology, Merck Sharp & Dohme and Pfizer/EMD Serono; and travel, accommodations and expenses support from Bristol Myers Squibb, Janssen Oncology and Roche. P.J.W. received honoraria from advisory/consultancy roles with AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Immunicom, Janssen, MSD, Merck, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi. G.L.B. declares no conflict of interest. B.A. received grants from P. Herzen Oncology Research Institute during the conduct of the study; grants from AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Astellas, MSD, Eisai and Roche; personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Astellas, MSD, Sanofi, Ferring, Ipsen, Eisai and Roche; and nonfinancial support from AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, Astellas, MSD, Sanofi, Ferring and Roche. B.M. received advisory/consultancy fees to the institution from Amgen, Pfizer and Roche; advisory/consultancy fees from Astellas Pharma, AstraZeneca, Bayer, Janssen, Pfizer and Roche; research funding support from Bayer, Janssen and Roche; and travel, accommodations and expenses support from Janssen-Cilag and Roche. B.K. declares no conflict of interest. J.D. is an employee of Genentech and has stock ownership of Roche. G.R. is an employee of Roche and has stock ownership of Roche. A.D. is an employee of Roche and has stock ownership of Roche. S.M. is an employee of Genentech and has stock ownership of Roche. P.W. is an employee of Genentech and has stock ownership of Roche. C.J.S. received advisory/consultancy fees from Astellas, Pfizer, Janssen, Dendreon, Bayer, Genentech and Glaxo; and institutional research funding support from Astellas, Pfizer, Janssen, Dendreon, Bayer and Sanofi.